Marcella Press
Cardiovascular Disease · Los Angeles, CANPI 1053427823
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Abbott at 48.7% of the total. Reporting peaked in 2023 at $16,721 and has fallen 84.0% since, to $2,668 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $301.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$25K
- Siemens Medical Solutions USA, Inc.$13K
- Edwards Lifesciences$5K
- Boston Scientific$3K
- Getinge USA Sales, LLC$2K
- Shockwave Medical, Inc$447
- plus $2K from 12 others
Across 17 payments — averaging $10,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$178K
What the payments were for
- Consulting fees$21,67543%
- Grants$2250%
- Travel & lodging$20,67341%
- Food & beverage$7,82916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 60 | $24,539 |
| Siemens Medical Solutions USA, Inc. | 22 | $12,835 |
| Edwards Lifesciences | 46 | $5,382 |
| Boston Scientific | 9 | $3,233 |
| Getinge USA Sales, LLC | 3 | $2,255 |
| Shockwave Medical, Inc | 6 | $447 |
| Philips North America LLC | 3 | $406 |
| Heartflow, Inc. | 2 | $283 |
| Medtronic(2 entities) | 4 | $211 |
| Abiomed | 2 | $167 |
| Penumbra, Inc. | 1 | $149 |
| Cvrx, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Cardiac Dimensions, Inc. | 2 | $64 |
| Chiesi USA, Inc. | 2 | $31 |
| Cardiva Medical, Inc. | 1 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$15,000
- MitraClip System$4,625
- GENERAL - THERAPIES$2,400
- CARDIOSAVE HYBRID, TYPE B PLUG$1,779
- NAEOTOM Alpha$1,366
- MitraClip$1,358
- EVOQUE$1,222
- Artis icono floor$1,174
- syngo dynamics$1,097
- ARTIS icono biplane$707
- PASCAL$698
- COROFLOW$583
- Vasoview Hemopro 2$476
- Dragonfly OCT$314
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$304
- DRAGONFLY OPSTAR$255
- FFRct$225
- Artis pheno$187
- 3F$182
- Emerge Push$166
How this compares
$50,402 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $250,483 |
| Repatha SureclickEvolocumab | 59 | $56,858 |
| FarxigaDapagliflozin Propanediol | 56 | $51,634 |
| EntrestoSacubitril/Valsartan | 45 | $48,011 |
| XareltoRivaroxaban | 36 | $46,001 |
| BrilintaTicagrelor | 13 | $13,974 |
| Ezetimibe | 274 | $8,288 |
| VascepaIcosapent Ethyl | 13 | $5,934 |
| Atorvastatin Calcium | 486 | $5,832 |
| Metoprolol Succinate | 377 | $5,353 |
| Rosuvastatin Calcium | 202 | $4,050 |
| Losartan Potassium | 281 | $3,988 |
| Amlodipine Besylate | 357 | $3,239 |
| Valsartan | 46 | $2,018 |
| Milrinone In 5% DextroseMilrinone Lactate/D5w | 23 | $1,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $123 | $46,00136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.